134 related articles for article (PubMed ID: 2938729)
21. Phase I study of oral menogaril administered daily for 14 consecutive days.
Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Stewart DJ; Eisenhauer EA; Skillings J; Pritchard KI; Buckman R; VAndenberg T; Verma S; Aitken S; Norris B
Ann Oncol; 1992 Mar; 3(3):201-4. PubMed ID: 1534021
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
25. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
26. Menogaril in the treatment of malignant mesothelioma: a phase II study.
Hudis CA; Kelsen DP
Invest New Drugs; 1992 Jul; 10(2):103-6. PubMed ID: 1386842
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Cheng EW; Hollander P
Am J Clin Oncol; 1988 Apr; 11(2):174-6. PubMed ID: 2965856
[TBL] [Abstract][Full Text] [Related]
28. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
[TBL] [Abstract][Full Text] [Related]
29. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Dodion P; Egorin MJ; Engisch KL; Bachur NR
Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of menogaril in advanced malignant melanoma. An EORTC trial.
Gundersen S; Monfardini S; Renard G; Van Glabbeke M; Pinedo H
Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1707-8. PubMed ID: 2962875
[No Abstract] [Full Text] [Related]
31. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
[TBL] [Abstract][Full Text] [Related]
33. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
34. Negative phase II trial of menogaril in advanced squamous, adeno- and large cell carcinoma of the lung.
Joss RA; Monfardini S; Hansen M; Dombernowsky P; Renard J; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):263-5. PubMed ID: 2833403
[No Abstract] [Full Text] [Related]
35. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group.
Sessa C; Kaye SB; Renard J; ten Bokkel Huinink W; Cavalli F
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):751-2. PubMed ID: 2523809
[No Abstract] [Full Text] [Related]
37. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo.
Adams EG; Bhuyan BK
Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401
[TBL] [Abstract][Full Text] [Related]
38. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Ratain MJ; Schilsky RL
Cancer Res; 1986 Sep; 46(9):4874. PubMed ID: 2942243
[No Abstract] [Full Text] [Related]
39. Anthracycline analogs: the past, present, and future.
Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
[No Abstract] [Full Text] [Related]
40. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
